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local weighted voting to assign a CT value to each voxel of 
the MR planning scan has been developed and tested.  
Methods: Forty men with ages ranging from 58 to 78 
undergoing prostate cancer radiation therapy treatment were 
scanned under a research protocol. Patients were positioned 
at MR in the treatment position on a Siemens Skyra 3T 
scanner. The planning MR sequence was a 3D, T2 weighted 
1.6 mm isotropic voxel SPACE sequence with field-of-view to 
cover the entire pelvis (ranging from 38 - 45 cm2) acquired in 
6 mins 40 s. All scans were contoured by 3 experienced 
observers. A conventional CT scan was acquired for the 
patient treatment plan, atlas generation, and to compare 
dose calculations.  
The atlas database is created by deformable registeration of 
the patient MR scan to the corresponding patient CT scan to 
form conjugate MR-CT pairs. To create synthetic CT scans 
from a subsequent patient planning MR scan the following 
steps are used: 1) each atlas MR scan is deformably 
registered to the patient planning MR scan; 2) for small voxel 
regions of the patient planning MR, the intensity is compared 
to the same voxel in all the registered atlas MR scans; 3) each 
atlas scan is assigned a weighting according to the similarity 
of the voxel values with the most similar having the highest 
weighting with all assigned weights summing to 1; 4) the CT 
values from the corresponding voxel of the conjugate CT 
atlas scans are added together using the previously 
determined weightings to provide the CT intensity value of 
that voxel of the synthetic CT scan.  
Results: Dose comparisons between the CT and synthetic CT 
scans created from the MR with the Eclipse AAA algorithm 
had an average difference of 0.3% and standard deviation of 
0.7% with tests performed using a leave-one-out approach. 
Gold fiducials are automatically segmented from MR scans 
(small field of view T1 flip 80 sequence) for image-guidance. 
Distortions and geometric accuracy of digitally reconstructed 
radiographs were tested with geometric phantoms and were 
within 1 mm of CT based values. 
Conclusions: MR-only planning using atlas-based electron 
density mapping to create synthetic CT scans for dose 
calculations has been shown to be an accurate method for 
prostate treatment planning. The method requires only a 
single conventional T2 weighted MR sequence. A prospective 
study using MR-only planning is currently in development to 
translate the MR-only workflow to clinical practice at our 
institution.  
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In a MR-only workflow, the planning CT scan used in the 
preparation of a radiotherapy treatment is replaced by MRI. 
MRI already outperforms CT in target and OAR definition in 
many cases, but for treatment planning the MRI is usually 
registered to a planning CT scan. For MR-only, the MRI scan is 
also needed for RT dose planning and image-guided 
radiotherapy at the treatment machine. The MR-only 
workflow allows us to abolish two preparation steps: the 
acquisition of the planning CT and the subsequent, 
registration of the planning CT with MRI. As the latter step 
can be inaccurate, the MR-only workflow improves both 
patient comfort and the accuracy of target localisation. 
For dose planning, electron densities now need to be derived 
from the MRI. Several methods have been developed for this 
purpose. One solution is to classify the tissue types in an MRI 
scan and assign Hounsfield Units (HU) accordingly. Errors in 
the Hounsfield Unit assignment can result in wrong dose 
deposition to both target and OAR. Therefore, QA of these 
scans is crucial for the RT chain. Since there is no CT scan 
available, the Hounsfield Unit map derived from MRI cannot 
be cross-checked with a regular planning CT. 
Although methods to derive a HU map from MRI are 
increasingly accurate, image artefacts in the MR scans 
themselves may corrupt the result. For example, an 
unnoticed paperclip in the scanner results in distorted MRI 
scans. For this reason, QA  has to be performed for each 
patient. Since this will be time-consuming, smart strategies 
are needed. 
In-vivo EPID dosimetry checks the consistency in the whole RT 
chain. Therefore, it is a suitable way to verify the integrity of 
the HU map derived from the MRI scan. The patient 
representation is checked by measuring transmission directly 
behind the patient with the EPID panel and comparing it with 
the calculated transmission from the MRI-derived HU map. 
The in-vivo EPID dosimetry method is fully automatic and 
easily performed for each individual patient. Furthermore, 
any significant under- or over dosage caused by an 
inconsistent HU assignment is reported in 3D. 
We tested the in-vivo dosimetry method for MR-only QA for 
the pelvic case. MR-only data was collected for prostate and 
rectum cancer patients on a Philips 3.0T MR system in 
treatment position on a flat table top. A 6-element phased-
array coil was strapped loosely on the pelvis to minimize 
body contour deformation. From the conventional MR DIXON 
scans, water and fat were classified. Bone was segmented 
with an atlas labelling technique into cortical bone and bone 
marrow. 
Subsequently, the clinical CT based VMAT plans were 
recalculated on MRI-derived HU maps with the same set of 
Monitor Units. The plans were compared using gamma 
evaluation and clinical dose parameters. 
In-vivo measured EPID dose of the first three fractions was 
back-projected to the patient in 3D. For the MR-only 
workflow the transmission was calculated from the MRI-
derived HU map. Dose differences were evaluated with a 3%-
3mm gamma criteria within the 50% isodose surface, 
consistent with our clinical practice. 
QA of a MR-only workflow is needed since errors in the MR-
derived HU maps directly effect dose distribution. In-vivo 
EPID dosimetry shows to be a promising method for QA of a 
MR-only workflow, since it checks the consistency in the 
whole RT chain in an automatic way. 
Symposium: Proton therapy I: future challenges 
SP-0023   
3D image and dose guidance 
L. Dong1 
1Scripps Proton Therapy Center, Medical Physics, San Diego, 
USA 
Abstract not received. 
SP-0024   
Current developments in proton and ion beam production 
and delivery 
O. Jäkel1 
1German Cancer Research Center, Medical Physics in 
Radiation Oncology, Heidelberg, Germany  
3rd ESTRO Forum 2015                                                                                                                                         S13 
 
Radiotherapy with proton and ion beams is currently in a 
phase where the facility concepts of the first generation are 
slowly shifting towards new accelerator concepts. In addition 
the majority of the new facilities is equipped with scanning 
beam delivery systems. In the first generation facilities 
“standard” accelerators were used, meaning cyclotrons and 
synchrotrons, which were not specifically designed to be very 
small. Moreover, the vast majority of these systems are 
equipped with so-called passive beam delivery systems. In 
the meantime there exist several concepts for compact 
accelerators, like laser induced particle acceleration, 
dielectric-wall accelerators, very compact gantry mounted 
cyclotrons and compact synchrotrons. Only the latter two 
concepts have been realized, however, in clinical facilities, 
aiming to provide smaller and thus also cheaper single room 
facilities.  
In contrast, the optimization of beam delivery concepts and 
especially fast scanning techniques for the treatment of 
moving tumors may have a stronger impact for the patients 
already on the short term. Besides fast energy switching the 
scanning speed is optimized in this case, to provide a 
drastically shortened treatment time and the potential for 
rescanning within a short time. Many of these improvements 
and developments are concentrating on proton therapy only, 
but also in the case of carbon ion facilities there is a 
continuous improvement of the classical synchrotron 
concepts towards fast switching of beam parameters to 
provide fast scanning and rescanning. In addition the first ion 
beam gantry came into clinical operation and novel, more 
compact, gantry concepts are under investigation. An 
overview of the latest developments, its status and 
perspectives is given in the presentation.  
   
SP-0025   
Intrafraction motion and proton beam scanning  
A. Knopf1 
1Institute of Cancer Research, Radiotherapy and Imaging, 
Sutton, United Kingdom  
 
Currently newly built particle therapy centers are mostly 
equipped with scanning beams, since they provide highly 
conformal dose distributions when treating static targets. 
However, scanned beams face significant challenges when 
applied to moving targets.  In addition to blurring effects, 
dose inhomogeneities can appear anywhere within a 
treatment field due to interplay between the delivery-time-
line and the time-line of motion. To mitigate motion effects, 
different approaches have been suggested. As the simplest 
solution, one can try to reduce the motion during treatment 
delivery through, for example, breath hold or gating 
techniques.  In this talk, we would like to concentrate on 
motion mitigation techniques that are unique for a scanned 
beam delivery, namely rescanning and tracking. 
The idea of rescanning is to statistically average out dose 
heterogeneities by repeatedly delivering the planned dose to 
the target with an accordingly reduced number of particles 
per scan. The risk of rescanning is the introduction of 
periodicity in the delivery time-line which can lead to 
interference phenomena with the periodicity of the patient 
motion. For a successful application of rescanning it is 
therefore essential to choose the right “flavor” of 
rescanning. Each specific way of scanning and each flavor of 
rescanning has its own characteristic delivery-time-line which 
is machine specific. In this presentation, we will show 
examples to emphasize that for a successful application of 
rescanning it is important to choose a way of scanning and a 
flavor of rescanning appropriate for your specific facility and 
adapted to the characteristics of each specific patient 
(motion characteristic, tumor size, tumor side). 
Beam tracking for particle therapy refers to the lateral 
adaptation of pencil beam position, combined with 
appropriate energy changes to modify the position of the 
Bragg peak in order to compensate for target motion in all 
directions. Tracking relies on motion monitoring; ideally, real 
time 3D imaging should be employed or alternatively pre-
treatment acquired 4DCT in combination with a motion 
surrogate. In current experiments the adaptation parameters 
are determined prior to treatment delivery based on 4DCT 
data, which leads to concerns about variations in patient 
anatomy and respiratory motion between the 4DCT scan and 
the time of treatment. For tracking, it is particularly 
important to minimize the time lag between the detection of 
a geometry change and the corresponding adaptation of the 
beam. By minimizing the time between pre-treatment 
imaging, potential online plan adaptation, and treatment 
delivery, these uncertainties can be reduced, but there is 
need to investigate the robustness of beam tracking, 
particularly over the time scales of fractionated delivery.  
An optimal outcome for moving target geometries is probably 
obtained by combining different motion mitigation 
approaches. As there exist many different motion scenarios 
there is an optimal way to account for motion effects for 
each scenario. Perhaps the ultimate solution for the 
treatment of moving targets with scanned particle beams 
would be the combination of real time tracking and 
rescanning, so called re-tracking. However, to implement this 
clinically, online on-board 3D imaging has to be improved. A 
lot of developments, simulations and verifications have to be 
performed before such a technique could be used clinically. 
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The use of radiotherapy as a method for tumor treatment is 
closely associated with toxicity in healthy tissues. Several 
methods have been developed to address this, using different 
techniques in an attempt to minimize the radiation dose to 
healthy tissues. Some techniques aim at reducing the clinical 
to planning target volume margins which account for the 
movement of the target as well as setup uncertainties. This 
presentation will focus on some of the essential interactions 
between internal and external immobilization techniques and 
image guided radiotherapy, beginning by describing three 
major factors which affect the outcome of radiotherapy: 
rotation, deformation and displacement. Some technique 
examples will be presented including immobilization of the 
prostate, the head and neck area and the rectum. The 
presentation will provide insights into the pros and cons of 
immobilization in an era of image guided radiotherapy.  
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